Our data demonstrate that the regulation of PGE2 production may in turn modulate T – regulatory cell development and function, the study. These findings suggest new therapeutic strategies targeting PGE2 in the prevention and treatment of cancer. . Kim Irwin 310-206-2805 University of California – Los Angeles health care.
The study appears in the 15th July 2005 edition of the peer-reviewed Journal of Immunology. We know that COX – 2 inhibitors like Celebrex decrease PGE2, as we discovered was was fueling the T – regulatory cells, we knew that we test a therapy we, said Dubinett, also a professor of pulmonary and critical care medicine and director of the Specialized Program Research Excellence in lung cancer. opens this discovery we we non non – toxic drugs to increase immune responses in cancer patients. .The examination revealed good cooperation between the surgical and medical teams, and that procedures are usually performed by an suitably experienced specialist surgeon.